Bio Rad实验室 BIO 深 沪
等待开盘 05-13 09:30:00 美东时间
242.42
-1.370
-0.56%
华盛通- 最 高246.195
- 今 开246.00
- 成交量 10.40万股
- 最 低 240.715
- 昨 收 243.79
- 总市值 64.88亿
- 52周最高 343.12
- 市盈率 静 8.70
- 换手率 0.39%
- 52周最低 211.43
- 委 比 75.31%
- 总股本 2676.16万
- 历史最高 832.70
- 量 比 0.36
- 振 幅 2.25%
- 历史最低 84.02
- 每 手 1
- 风险率 28.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 苹果获多家机构上调目标价，最高至335美元；闪迪获华尔街大行看多至2000美元
今日重点评级关注：Benchmark：维持史密斯微软件"买入"评级，目标价从2美元升至2.5美元；Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元
05-04 16:04
Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU
U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on Hormuz news and Trump set 25% EU auto tariffs.
05-02 01:11
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.
05-01 22:03
财报速睇 | Bio Rad实验室 2026财年Q1营收5.92亿美元，同比增长1.1%；归母净利润亏损5.27亿美元，由盈转亏
华盛资讯5月1日讯，Bio Rad实验室公布2026财年Q1业绩，公司Q1营收5.92亿美元，同比增长1.1%，归母净利润亏损5.27亿美元，由盈转亏。
05-01 08:35
Bio-Rad Laboratories Lowers FY2026 Sales Guidance from $2.596B-$2.622B to $2.506B-$2.596B vs $2.630B Est
Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2.506 billion-$2.596 billion vs $2.630 billion estimate.
05-01 06:05
Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call
Bio-Rad Laboratories (NYSE:BIO) held its first-quarter earnings conference call...
05-01 05:46
Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
Longleaf Partners Global Fund exits BIO, DIS among Q1 moves
Longleaf Partners Global Fund said that it ended the first quarter of 2026 with a P/V in the mid-50s%. The fund, in its quarterly commentary, said that FedEx (FDX) and Glanbia (GLAPY) were top contrib...
04-21 00:16
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $300
Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $375 to $300.
04-07 20:55
